Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome …
